<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Since studies by Allen et al </plain></SENT>
<SENT sid="1" pm="."><plain>[1] calcium <z:chebi fb="68" ids="48706">antagonists</z:chebi> have been commonly used for prevention of <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> in patients suffering from <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> (SAH) </plain></SENT>
<SENT sid="2" pm="."><plain>Vasodilatation-induced <z:hpo ids='HP_0002615'>hypotension</z:hpo>, increase of cardiac output and intrapulmonary shunting (Qs/Qt) are wellknown cardiovascular effects </plain></SENT>
<SENT sid="3" pm="."><plain>These problems are discussed in light of previous reports and present case study of a 34-year-old woman treated with the calcium <z:chebi fb="68" ids="48706">antagonist</z:chebi> nimodipine after SAH </plain></SENT>
<SENT sid="4" pm="."><plain>Reproducible results from invasive haemodynamic monitoring (Swan-Ganz-thermodilution catheter) indicated correlation between nimodipine application and increased intrapulmonary shunting </plain></SENT>
<SENT sid="5" pm="."><plain>This effect can be hazardous for SAH patients because preexisting cerebral ischemic <z:mp ids='MP_0005039'>hypoxia</z:mp> makes them particularly susceptible to additional decrease in oxygen supply </plain></SENT>
</text></document>